66909-29-3

Basic information

• Product Name: 6-Chloro-5-methylpyridine-3-carboxylic acid
• Synonyms: 6-Chloro-5-methylpyridine-3-carboxylic acid;6-Chloro-5-methylnicotinic acid;6-Chloro-5-methylpyridine-3-carboxylic acid, 5-Carboxy-2-chloro-3-methylpyridine;5-Carboxy-2-chloro-3-methylpyridine
• CAS NO: 66909-29-3
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 172
• Mol File: 66909-29-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)
• EPA Substance Registry System: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)

Safety Data

• Hazardous Substances Data: 66909-29-3(Hazardous Substances Data)

Usage

Description

6-Chloro-5-methylpyridine-3-carboxylic acid is an organic compound characterized by its chlorinated and methylated pyridine ring structure, featuring a carboxylic acid functional group. This molecule is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to be further functionalized and modified makes it a versatile building block for drug development.
Used in the Treatment of ROR-γ-Mediated Diseases:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a ROR-γ (Retinoic Acid Receptor-Related Orphan Receptor Gamma) inhibitor for the treatment of ROR-γ-mediated diseases. By targeting and inhibiting the ROR-γ receptor, this compound can potentially modulate immune responses and treat conditions such as autoimmune disorders, inflammatory diseases, and certain types of cancer.

Upstream product

• 176433-43-5 6-chloro-5-methylpyridine-3-carboxaldehyde 
• 30574-97-1 tiglonitrile 
• 4403-61-6 2-methyl-2-butene nitrile 
• 59782-89-7 2-Chloro-5-iodo-3-methylpyridine 
• 124-38-9 carbon dioxide 

Downstream Products

• 942511-70-8 6-chloro-5-methylnicotinic acid ethyl ester 
• 1122090-09-8 isopropyl 6-chloro-5-methylnicotinate 
• 1122090-20-3 6-(Isopropylamino)-5-methylnicotinic acid 
• 1516901-64-6 (S)-N-(3-(2-ethyl-4-(5-(6-isopropyl-5-methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186617-59-3 N-((S)-3-{4-[5-(6-diethylamino-5-methyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186618-30-3 N-((S)-3-{2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]phenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186617-62-8 2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-phenol 
• 1186618-27-8 C₂₄H₃₁N₅O₃ 
• 1186617-39-9 5-methyl-6-pyrrolidin-1-yl-nicotinic acid 

Relevant articles and documents

First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump

Overexpression of efflux pumps is an important mechanism of bacterial resistance that results in the extrusion of antimicrobial agents outside the bacterial cell. Inhibition of such pumps appears to be a promising strategy that could restore the potency of existing antibiotics. The NorA efflux pump of Staphylococcus aureus confers resistance to a wide range of unrelated substrates, such as hydrophilic fluoroquinolones, leading to a multidrug-resistance phenotype. In this work, approximately 150 heterocyclic boronic species were evaluated for their activity against susceptible and resistant strains of S. aureus. Twenty-four hit compounds, although inactive when tested alone, were found to potentiate ciprofloxacin activity by a 4-fold increase at concentrations ranging from 0.5 to 8 μg/mL against S. aureus 1199B, which overexpresses NorA. Boron-free analogues showed no biological activity, thus revealing that the boron atom is crucial for biological activity. This work describes the first reported efflux pump inhibitory activity of boronic acid derivatives.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.